Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Microbial Biosensors01:17

Microbial Biosensors

88
Microbial biosensors are analytical devices that utilize living microbes to detect specific substances through measurable signals. These devices consist of two main components: biosensing organisms and signal-transducing elements. Biosensing organisms, such as Escherichia coli or Saccharomyces cerevisiae, are typically housed in multiwell plates connected to transducers, enabling rapid, real-time detection of target analytes.Signal Generation MechanismWhen a target analyte—such as...
88
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

34
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
34

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Study rules out zinc as a potential biomarker of Alzheimer's disease.

Bioanalysis·2014
Same author

New compound could be an ideal candidate for visual restoration in patients with degenerative retinal disorders.

Future medicinal chemistry·2014
Same author

Interview with Paul Selzer.

Future medicinal chemistry·2014
Same author

New method created to easily and safely detect prostate cancer.

Bioanalysis·2013
Same author

Nanoparticles deliver a sting to HIV‑1 infectivity.

Nanomedicine (London, England)·2013
Same author

Using nanomedicine to resolve inflammation and prevent tissue damage.

Nanomedicine (London, England)·2013

Related Experiment Video

Updated: Apr 29, 2026

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
10:46

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

10.6K

Scientists develop new biosensor to test for Alzheimer's disease

James Potticary

    Bioanalysis
    |May 16, 2014
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
    09:47

    Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

    Published on: December 15, 2023

    2.0K
    Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
    05:17

    Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

    Published on: April 18, 2025

    1.1K

    Related Experiment Videos

    Last Updated: Apr 29, 2026

    Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
    10:46

    Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

    Published on: May 3, 2017

    10.6K
    Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
    09:47

    Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

    Published on: December 15, 2023

    2.0K
    Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
    05:17

    Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

    Published on: April 18, 2025

    1.1K